Profile
Business Description
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist that resolves chronic inflammation and limits fibrosis in animal and human models. Lenabasum is currently being evaluated in dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of other preclinical drug candidates from its endocannabinoid system platform.
Company Info
Address:
500 River Ridge Drive
Norwood, MA 02062 US
Telephone:
617.963.0100
Fax:
617.663.6085
Email:
info@corbuspharma.com
Industry Classifications
Sector:
Biopharmaceutical
Industry:
Biotechnology
NAICS:
325412 – Pharmaceutical Preparation Manufacturing
SIC:
2834 – Pharmaceutical Preparations